Clinical Trial

Phase 2a Trial of Alpibectir Plus Ethionamide for Tuberculosis Meningitis

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
AlpE is a novel drug combination under development for the treatment of TB, with several positive attributes for TBM, including rapid bactericidal activity. The current trial aims to assess the plasma and CSF PK, as well as the safety and tolerability of alpibectir and three doses of Eto in patients with newly diagnosed TBM. Additionally, it is attended to investigate the effect of AlpE on the PK and efficacy of DTG during the first month of antiretroviral treatment (ART) for Human Immunodeficiency Virus (HIV)-positive patients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-16.
Trial Details
NCT Number NCT07350174
Lead Sponsor BioVersys AG
Conditions Tuberculosis Meningitis
Enrollment 64 participants
Start Date 2026-03-30
Primary Completion 2028-03-30 (estimated)
Study Completion 2028-10-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-03